Improvement of RA With ABBV-599 Attributed to JAK Inhibitor
Researchers investigated whether ABBV-599 could increase the treatment response for patients with RA compared with JAK inhibitor or BTK inhibitor alone.
Rheumatoid Arthritis Headlines
RHEUMATOID ARTHRITIS HEADLINES
Infectious Risk Similar Between cDMARDs and TNFis With Concomitant Methotrexate for RA
Researchers investigated the risk for infection between leflunomide vs TNFi and tacrolimus vs TFNi among patients with rheumatoid arthritis treated with concomitant methotrexate.
Medication Dosages Predict Successful Control of Difficult-to-Treat RA
To explore predictive prognosis indicators, researchers studied factors of patients with RA who have received successful treatment with DMARDs.
Factors Linked to Poor Prognosis of RA-Associated Interstitial Lung Disease Determined
Researchers assessed the effect of clinical characteristics and treatment options on the prognosis of patients with rheumatoid arthritis-associated interstitial lung disease.
Divergence Between Physician- and Patient-Reported Measures of Tofacitinib Treatment Response in RA
Researchers compared physician- and patient-reported measures of tofacitinib therapy to determine the impact of long-term treatment among patients with rheumatoid arthritis.
Patients With RA Benefit From Treatment With Biologic and Targeted DMARD Therapy
Researchers investigated treatment responses to sequential lines of biologic or targeted synthetic DMARD therapy in patients with RA to determine if they experienced benefits from a trial-and-error approach to treatment.
Risk for Cardiovascular Disease Significantly Higher Among Patients With RA vs General Population
Researchers explored the association between rheumatoid arthritis and cardiovascular disease among US adults aged 20 years and older.
Passive Smoking Linked to Increased Risk for Rheumatoid Arthritis
Passive smoking during childhood and/or adulthood is ass.ociated with increased risk of rheumatoid arthritis
DMARDs Not Linked to Alzheimer Disease Risk in Older Adults With RA
The main outcome was ADRD onset examined in four alternative analysis schemes.
Little Variation in Risk for Acute Coronary Syndrome Among Patients With RA Initiating Different bDMARDs
Researchers assessed the risks for short-, intermediate-, and long-term acute coronary syndrome among patients with rheumatoid arthritis initiating treatment with biologic disease-modifying antirheumatic drugs.
![Treatments for JSpA are based on agents evaluated in adult SpA.[7,11] The 2011 ACR guidelines are for JIA and are not specific to JSpA.[11] The algorithms for peripheral disease consider the number of active joints and prognosis.[11] First-line treatment is essentially a brief trial of NSAID monotherapy. For persistent activity, the ACR suggests adding or switching to a disease-modifying anti-rheumatic drug (DMARD), such as methotrexate, sulfasalazine, or leflunomide. Glucocorticoid intraarticular injections are advised for all children with active arthritis.[11] DMARDs are effective for peripheral JIA but have not been proven effective for axial disease or enthesitis in JSpA.[7] However, open-label studies indicate sulfasalazine improves symptoms in juvenile AS, ERA, and PsA.[7] For JIA refractory to NSAIDs and DMARDs, ACR guidelines recommend a tumor necrosis factor (TNF) inhibitor.[11] The rate and type of treatment escalation depends on disease activity.[7]](https://www.rheumatologyadvisor.com/wp-content/uploads/sites/18/2019/01/6prescriptionmedicationts1_1032644.jpg)
DMARD Prescription Rates Low for Older Adults With Rheumatoid Arthritis
Older adults with rheumatoid arthritis (RA) are undermedicated with disease-modifying antirheumatic drugs.
RA Subgroup Shows High Levels of Pain, Fatigue, and Psychosocial Distress 3 Years After Diagnosis
Researchers assessed data from a subgroup of patients with rheumatoid arthritis, based on their health status, 3 years after diagnosis.
Upadacitinib Use Does Not Affect Pneumococcal Vaccine Response in Patients With RA
Researchers studied the response to pneumococcal vaccination among patients with rheumatoid arthritis receiving upadacitinib and methotrexate.
Greater Pain Relief With Baricitinib vs Methotrexate in Patients With Early RA
In a post hoc analysis, researchers assessed improvements in pain with baricitinib vs methotrexate among patients with early rheumatoid arthritis.
Factors Linked to Excess Disability Identified in Rheumatoid Arthritis
The odds of being in the high HAQ trajectories were increased in association with higher pain, fatigue, and depressive symptoms.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...